Auna S.A. (NYSE:AUNA) Short Interest Update

Auna S.A. (NYSE:AUNA) was the target of a significant increase in short interest during the month of February. As of February 27th, there was short interest totaling 436,807 shares, an increase of 40.1% from the February 12th total of 311,888 shares. Approximately 0.6% of the company’s stock are short sold. Based on an average daily trading volume, of 590,559 shares, the short-interest ratio is presently 0.7 days. Based on an average daily trading volume, of 590,559 shares, the short-interest ratio is presently 0.7 days. Approximately 0.6% of the company’s stock are short sold.

Auna Stock Performance

Shares of NYSE:AUNA traded up $0.10 on Friday, reaching $5.08. 508,288 shares of the company’s stock were exchanged, compared to its average volume of 567,258. The firm has a market capitalization of $376.19 million, a price-to-earnings ratio of 14.12 and a beta of 2.09. Auna has a fifty-two week low of $4.46 and a fifty-two week high of $7.50. The business’s 50-day moving average is $4.97 and its two-hundred day moving average is $5.42. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 1.87.

Auna (NYSE:AUNA) last posted its quarterly earnings results on Tuesday, March 10th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.11 by $0.42. The business had revenue of $336.67 million during the quarter, compared to analyst estimates of $1.08 billion. Auna had a net margin of 2.13% and a return on equity of 19.23%. As a group, equities research analysts forecast that Auna will post 0.5 EPS for the current year.

Wall Street Analyst Weigh In

AUNA has been the topic of a number of research analyst reports. HSBC upgraded shares of Auna from a “hold” rating to a “buy” rating and set a $6.90 price objective on the stock in a research note on Wednesday, January 21st. Zacks Research upgraded shares of Auna from a “strong sell” rating to a “strong-buy” rating in a research note on Monday, February 9th. Wall Street Zen upgraded Auna from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 28th. Jefferies Financial Group began coverage on Auna in a report on Friday, January 16th. They issued a “buy” rating and a $9.00 price objective for the company. Finally, JPMorgan Chase & Co. restated a “neutral” rating and set a $6.00 price objective (down from $13.50) on shares of Auna in a research note on Tuesday, November 18th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Auna presently has an average rating of “Moderate Buy” and a consensus price target of $7.30.

Institutional Trading of Auna

Several hedge funds have recently made changes to their positions in AUNA. Fiera Capital Corp grew its stake in Auna by 2.7% during the 2nd quarter. Fiera Capital Corp now owns 1,558,358 shares of the company’s stock worth $9,662,000 after buying an additional 40,673 shares during the last quarter. Heron Bay Capital Management bought a new stake in Auna in the fourth quarter valued at $138,000. Squarepoint Ops LLC acquired a new position in shares of Auna during the fourth quarter valued at $196,000. Goldman Sachs Group Inc. acquired a new position in shares of Auna during the first quarter valued at $219,000. Finally, Citadel Advisors LLC grew its position in shares of Auna by 28.9% during the third quarter. Citadel Advisors LLC now owns 36,352 shares of the company’s stock worth $244,000 after acquiring an additional 8,147 shares during the last quarter.

Auna Company Profile

Auna, listed on the New York Stock Exchange under the ticker symbol AUNA, is a Peruvian integrated healthcare services company headquartered in Lima. The firm operates a diversified care network that spans hospitals, outpatient medical centers, diagnostic imaging and laboratory facilities, as well as optical and dental clinics. Auna’s organizational structure is designed to support a continuum of care model, offering both general and specialized treatments across multiple touchpoints.

The company delivers a broad range of clinical services, including emergency care, inpatient and outpatient surgery, obstetrics, cardiology, oncology, orthopedics, and other specialized disciplines.